Rethinking the Gut Health Craze: The Science Behind Microbiome Research and Probiotic Skepticism
In recent years, the gut microbiome has emerged as a glamorous frontier in health and wellness, touted as a panacea ...
Medicare’s Bold Step: The First 10 Drug Price Negotiations and Their Ripple Effects
In a historic policy shift, Medicare has begun direct negotiations on the prices of 10 widely used prescription drugs, marking ...
The Rising Tide of Healthcare Worker Strikes: A Reflection of Economic and Political Tensions
In recent months, a surge in healthcare worker strikes has emerged across the United States, highlighting deep-seated economic and political ...
Donanemab’s FDA Panel Approval: A Breakthrough Moment for Alzheimer’s—and a Cautionary Tale for Biotech
In a highly anticipated decision, an advisory panel to the U.S. Food and Drug Administration (FDA) voted overwhelmingly to support ...
NIH Long COVID Findings: Progress, Frustration, and the Unfinished Puzzle of Post-Viral Illness
Nearly four years into the COVID-19 pandemic, Long COVID remains one of its most haunting legacies—a shadow epidemic affecting millions ...
Second Opinion, First Defendant: How AI Is Redrawing the Legal Map in Radiology
Who gets sued when the algorithm is wrong? That question, once theoretical, is now central to a field undergoing radical ...
RSV Vaccines for the Youngest and the Oldest: A Public Health Milestone—and a Public Trust Test
After decades of research and anticipation, the medical community is celebrating a significant breakthrough: the arrival of respiratory syncytial virus ...
The WHO Pandemic Treaty Debate: Global Unity or Sovereign Resistance?
As memories of COVID-19's global chaos linger, the international community is grappling with an ambitious yet polarizing idea: a legally ...
Google’s MedLM and the Future of AI in Healthcare: Promise, Pitfalls, and Polarization
Google's latest foray into healthcare innovation, the announcement of its MedLM artificial intelligence platform, has ignited both excitement and apprehension ...
A Generation in Distress: New CDC Findings Reveal Worsening Mental Health Among Teen Girls
A new report from the Centers for Disease Control and Prevention (CDC) paints a grim portrait of adolescent mental health ...
Ozempic and Wegovy Shortages: A Weight Loss Revolution Stalled by Supply Constraints
In a healthcare landscape often defined by incremental change, few pharmaceuticals have sparked as much fervent demand—and ensuing controversy—as Ozempic ...
When Bird Flu Crosses New Frontiers: The Emerging Threat from Dairy Cows to Humans
In an era defined by the unpredictable interplay between human systems and the natural world, the emergence of highly pathogenic ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read morePopular
-
The Importance of Access Control in the Workplace
-
Drug Pricing Transparency in an Era of Political Polarization: What MedPricer’s Data Reveals About a Contested Policy Landscape
-
Employer-Sponsored Insurance Is Breaking Down. Price Data Tells You Where It’s Happening First.
-
State Regulators and the Federal Data Gap: How MedPricer Fills What CMS Leaves Incomplete
-
The Price Database That Reporters Keep Ignoring
